Investigational therapies targeting lymphocyte antigens for the treatment of non-Hodgkin's lymphoma

Expert Opinion on Investigational Drugs

Volumn 24, Issue 7, 2015, Pages 897-912

  Merli, Michele ^a   Ferrario, Andrea ^a   Maffioli, Margherita ^a   Arcaini, Luca ^b   Passamonti, Francesco ^a  

^a OSPEDALE DI CIRCOLO   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

Author keywords

Antibody drug conjugates; Bispecific T cell engagers; CD20; CD30; CTLA 4; Immune checkpoint inhibitors; MAb; Non Hodgkin's lymphoma; PD 1; PD L1

Indexed keywords

ALEMTUZUMAB; BLINATUMOMAB; BRENTUXIMAB VEDOTIN; CD19 ANTIGEN; CD20 ANTIGEN; CD22 ANTIGEN; CD30 ANTIGEN; CD40 ANTIGEN; CD52 ANTIGEN; CHEMOKINE RECEPTOR CCR4; COLTUXIMAB RAVTANSINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DACETUZUMAB; EPRATUZUMAB; INOTUZUMAB OZOGAMICIN; IPILIMUMAB; LUCATUMUMAB; LYMPHOCYTE ANTIGEN; MONOCLONAL ANTIBODY; NIVOLUMAB; OBINUTUZUMAB; OFATUMUMAB; PEMBROLIZUMAB; PIDILIZUMAB; PINATUZUMAB VEDOTIN; POLATUZUMAB VEDOTIN; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; RITUXIMAB; UNINDEXED DRUG; ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; MEMBRANE ANTIGEN;

ANGIOIMMUNOBLASTIC T CELL LYMPHOMA; APHASIA; B CELL LYMPHOMA; BRAIN DISEASE; CHRONIC LYMPHATIC LEUKEMIA; CUTANEOUS T CELL LYMPHOMA; CYTOTOXICITY; DIARRHEA; DISORIENTATION; DRUG MECHANISM; DRUG TARGETING; ENTEROPATHY ASSOCIATED T CELL LYMPHOMA; FATIGUE; FEBRILE NEUTROPENIA; FOLLICULAR LYMPHOMA; HODGKIN DISEASE; HUMAN; LARGE CELL LYMPHOMA; MANTLE CELL LYMPHOMA; MARGINAL ZONE LYMPHOMA; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; PERIPHERAL NEUROPATHY; PERIPHERAL T CELL LYMPHOMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT DISEASE; REVIEW; SEIZURE; SEPSIS; T CELL LEUKEMIA; T CELL LYMPHOMA; THYROID DISEASE; TREMOR; WALDENSTROEM MACROGLOBULINEMIA; EXPERIMENTAL THERAPY; IMMUNOLOGY; LYMPHOMA, NON-HODGKIN; T LYMPHOCYTE;

ANTIBODIES, MONOCLONAL; ANTIGENS, SURFACE; ANTINEOPLASTIC AGENTS; HUMANS; IMMUNOCONJUGATES; LYMPHOMA, NON-HODGKIN; T-LYMPHOCYTES; THERAPIES, INVESTIGATIONAL;

EID: 84934909085     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2015.1038342     Document Type: Review

References (109)

1. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol 1998;16(8):2825-33
2. Uchida J, Hamaguchi Y, Oliver JA, et al. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J Exp Med 2004;199(12):1659-69
3. Cheson BD, Leonard JP. Monoclonal antibody therapy for b-cell non-Hodgkin's lymphoma. N Engl J Med 2008;359(6):613-26
4. Alduaij W, Ivanov A, Honeychurch J, et al. Novel type ii anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actindependent, lysosome-mediated cell death in b-cell malignancies. Blood 2011;117(17):4519-29
5. Davis TA, Grillo-Lopez AJ, White CA, et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol 2000;18(17):3135-43
6. Mossner E, Brunker P, Moser S, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated b-cell cytotoxicity. Blood 2010;115(22):4393-402
7. Bologna L, Gotti E, Manganini M, et al. Mechanism of action of type ii, glycoengineered, anti-CD20 monoclonal antibody GA101 in b-chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumab. J Immunol 2011;186(6):3762-9
8. Herter S, Birk MC, Klein C, et al. Glycoengineering of therapeutic antibodies enhances monocyte/macrophage-mediated phagocytosis and cytotoxicity. J Immunol 2014;192(5):2252-60
9. Salles G, Morschhauser F, Lamy T, et al. Phase 1 study results of the type ii glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in b-cell lymphoma patients. Blood 2012;119(22):5126-32
10. Salles GA, Morschhauser F, Solal-Celigny P, et al. Obinutuzumab (GA101) in patients with relapsed/refractory indolent non-Hodgkin lymphoma: Results from the phase II GAUGUIN study. J Clin Oncol 2013;31(23):2920-6
11. Sehn LH, Assouline SE, Stewart DA, et al. A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive b-cell malignancies. Blood 2012;119(22):5118-25
12. Sehn LH, Goy A, Offner FC, et al. Randomized phase II trial comparing GA101 (obinutuzumab) with rituximab in patients with relapsed CD20 indolent b-cell non-Hodgkin lymphoma: Preliminary analysis of the gauss study. ASH Annual Meeting Abstracts 2011;118(21):269
13. Radford J, Davies A, Cartron G, et al. Obinutuzumab (GA101) plus chop or Fc in relapsed/refractory follicular lymphoma: Results of the GAUDI study (bo21000). Blood 2013;122(7):1137-43
14. Dyer MJ, Grigg A, Gonzalez M, et al. Obinutuzumab (GA101) in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (chop) or bendamustine in patients with previously untreated follicular lymphoma (fl): Results of the phase Ib GAUDI study (bo21000). ASH Annual Meeting Abstracts 2012;120(21):3686
15. Dyer MJ, Grigg AP, González Díaz M, et al. Obinutuzumab (GA101) in combination with chop (cyclophosphamide, doxorubicin, vincristine and prednisone) or bendamustine for the first-line treatment of follicular non-Hodgkin lymphoma: Final results from the maintenance phase of the phase Ib GAUDI study. ASH Annual Meeting Abstract 2014;124:abstract 1743
16. Fowler NH, Davis RE, Rawal S, et al. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: An open-label, phase II trial. Lancet Oncol 2014;15(12):1311-18
17. Morschhauser F, Salles G, Le Gouill S, et al. A phase Ib study of obinutuzumab combined with lenalidomide for relapsed/refractory follicular b-cell lymphoma. ASH Annual Meeting Abstract 2014;124:abstract 4458
18. Morschhauser FA, Cartron G, Thieblemont C, et al. Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large b-cell lymphoma or mantle-cell lymphoma: Results from the phase II GAUGUIN study. J Clin Oncol 2013;31(23):2912-19
19. Teeling JL, French RR, Cragg MS, et al. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 2004;104(6):1793-800
20. Coiffier B, Lepretre S, Pedersen LM, et al. Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory b-cell chronic lymphocytic leukemia: A phase 1-2 study. Blood 2008;111(3):1094-100
21. Hagenbeek A, Gadeberg O, Johnson P, et al. First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: Results of a phase 1/2 trial. Blood 2008;111(12):5486-95
22. Czuczman MS, Fayad L, Delwail V, et al. Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: Results from a multicenter study. Blood 2012;119(16):3698-704
23. Czuczman MS, Hess G, Gadeberg OV, et al. Chemoimmunotherapy with ofatumumab in combination with chop in previously untreated follicular lymphoma. Br J Haematol 2012;157(4):438-45
24. Czuczman MS, Kahanic S, Forero A, et al. Results of a phase II study of bendamustine and ofatumumab in untreated indolent b cell non-Hodgkin's lymphoma. Ann Hematol 2015;94(4):633-41
25. Peyrade F, Serge B, Delwail V, et al. Pre-phase chemotherapy followed by ofatumumab (ofa) and reduced dose chop (ofa-mini-chop) for patients over 80 years with diffuse large b-cell lymphoma (DLBCL)-a lymphoma study association (LYSA) prospective phase II study (lnh09-7b). ASH Annual Meeting Abstract 2014;124:abstract 3042
26. Matasar MJ, Czuczman MS, Rodriguez MA, et al. Ofatumumab in combination with ice or dhap chemotherapy in relapsed or refractory intermediate grade b-cell lymphoma. Blood 2013;122(4):499-506
27. van Imhoff GW, McMillan A, Matasar MJ, et al. Ofatumumab versus rituximab salvage chemoimmunotherapy in relapsed or refractory diffuse large b-cell lymphoma: The Orcharrd study (omb110928). ASH Annual Meeting Abstract 2014;124:abstract 630
28. Lunning MA, Vose JM, Schreeder MT, et al. Ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody (mAb), in combination with tgr-1202, a next generation once daily pi3kd inhibitor, demonstrates activity in heavily pre-treated and high-risk chronic lymphocytic leukemia (CLL) and b-cell. ASH Annual Meeting Abstract 2014;124:abstract 801
29. Sharman JP, Farber CM, Mahadevan D, et al. Ublituximab (tg-1101), a novel glycoengineered anti-CD20 monoclonal antibody, in combination with ibrutinib is highly active in patients with relapsed and/or refractory CLL and MCL; results of a phase II trial. ASH Annual Meeting Abstract 2014;124:abstract 4679
30. Goldenberg DM, Rossi EA, Stein R, et al. Properties and structure-function relationships of veltuzumab (ha20), a humanized anti-CD20 monoclonal antibody. Blood 2009;113(5):1062-70
31. Morschhauser F, Leonard JP, Fayad L, et al. Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: Phase I/II results. J Clin Oncol 2009;27(20):3346-53
32. Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IGG Fc receptor FcgammaRIIIa gene. Blood 2002;99(3):754-8
33. Weng WK, Levy R. Two immunoglobulin g fragment c receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003;21(21):3940-7
34. Morschhauser F, Marlton P, Vitolo U, et al. Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mab, in patients with relapsed/refractory follicular lymphoma. Ann Oncol 2010;21(9):1870-6
35. Tobinai K, Ogura M, Kobayashi Y, et al. Phase i study of ly2469298, an Fcengineered humanized anti-CD20 antibody, in patients with relapsed or refractory follicular lymphoma. Cancer Sci 2011;102(2):432-8
36. Leonard JP, Coleman M, Ketas J, et al. Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma. J Clin Oncol 2005;23(22):5044-51
37. Micallef IN, Maurer MJ, Wiseman GA, et al. Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large b-cell lymphoma. Blood 2011;118(15):4053-61
38. Leonard JP, Coleman M, Ketas JC, et al. Phase i/ii trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma. J Clin Oncol 2003;21(16):3051-9
39. Leonard JP, Coleman M, Ketas JC, et al. Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: Phase I/II clinical trial results. Clin Cancer Res 2004;10(16):5327-34
40. Leonard JP, Schuster SJ, Emmanouilides C, et al. Durable complete responses from therapy with combined epratuzumab and rituximab: Final results from an international multicenter, phase 2 study in recurrent, indolent, non-Hodgkin lymphoma. Cancer 2008;113(10):2714-23
41. Strauss SJ, Morschhauser F, Rech J, et al. Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma. J Clin Oncol 2006;24(24):3880-6
42. Grant BW, Jung SH, Johnson JL, et al. A phase II trial of extended induction epratuzumab and rituximab for previously untreated follicular lymphoma: Calgb 50701. Cancer 2013;119(21):3797-804
43. Hamadani M, Fanale MA, Bello CM, et al. Safety profile and clinical response to medi-551, a humanized monoclonal anti-CD19, in a phase 1/2 study in adults with relapsed or refractory advanced b-cell malignancies. ASH Annual Meeting Abstract 2013;122:abstract 1810
44. Ogura M, Ando K, Uike N, et al. A multicenter phase I study of the humanized anti-CD19 monoclonal antibody, medi-551, in patients with relapsed or refractory b-cell lymphoma and multiple myeloma. ASH Annual Meeting Abstract 2014;124:abstract 1756
45. Luqman M, Klabunde S, Lin K, et al. The antileukemia activity of a human anti-CD40 antagonist antibody, hcd122, on human chronic lymphocytic leukemia cells. Blood 2008;112(3):711-20
46. Byrd JC, Kipps TJ, Flinn IW, et al. Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (hcd122) in relapsed chronic lymphocytic leukemia. Leukemia Lymphoma 2012;53(11):2136-42
47. Fanale M, Assouline S, Kuruvilla J, et al. Phase Ia/II, multicentre, open-label study of the CD40 antagonistic monoclonal antibody lucatumumab in adult patients with advanced non-Hodgkin or Hodgkin lymphoma. Br J Haematol 2014;164(2):258-65
48. Law CL, Gordon KA, Collier J, et al. Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal antibody, sgn-40. Cancer Res 2005;65(18):8331-8
49. Forero-Torres A, Bartlett N, Beaven A, et al. Pilot study of dacetuzumab in combination with rituximab and gemcitabine for relapsed or refractory diffuse large b-cell lymphoma. Leuk Lymphoma 2013;54(2):277-83
50. Lopez A, Gutierrez A, Palacios A, et al. Gemox-r regimen is a highly effective salvage regimen in patients with refractory/relapsing diffuse large-cell lymphoma: A phase II study. Eur J Haematol 2008;80(2):127-32
51. Rossmann ED, Lundin J, Lenkei R, et al. Variability in b-cell antigen expression: Implications for the treatment of b-cell lymphomas and leukemias with monoclonal antibodies. Hematol J 2001;2(5):300-6
52. Jiang L, Yuan CM, Hubacheck J, et al. Variable CD52 expression in mature T cell and NK cell malignancies: Implications for alemtuzumab therapy. Br J Haematol 2009;145(2):173-9
53. Mone AP, Cheney C, Banks AL, et al. Alemtuzumab induces caspaseindependent cell death in human chronic lymphocytic leukemia cells through a lipid raft-dependent mechanism. Leukemia 2006;20(2):272-9
54. Demko S, Summers J, Keegan P, et al. FDA drug approval summary: Alemtuzumab as single-agent treatment for b-cell chronic lymphocytic leukemia. Oncologist 2008;13(2):167-74
55. Enblad G, Hagberg H, Erlanson M, et al. A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral t-cell lymphomas. Blood 2004;103(8):2920-4
56. Gallamini A, Zaja F, Patti C, et al. Alemtuzumab (campath-1h) and chop chemotherapy as first-line treatment of peripheral t-cell lymphoma: Results of a gitil (gruppo italiano terapie innovative nei linfomi) prospective multicenter trial. Blood 2007;110(7):2316-23
57. Lundin J, Hagberg H, Repp R, et al. Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome. Blood 2003;101(11):4267-72
58. Binder C, Ziepert M, Pfreundschuh M, et al. Cho(e)p-14 followed by alemtuzumab consolidation in untreated peripheral t cell lymphomas: Final analysis of a prospective phase II trial. Ann Hematol 2013;92(11):1521-8
59. d'Amore F, Leppa S, da Silva MG, et al. First interim efficacy and safety analysis of an international phase III randomized trial in newly diagnosed systemic peripheral t-cell lymphoma treated with chemotherapy with or without alemtuzumab and consolidated by high dose therapy. ASH Annual Meeting Abstracts 2012;120(21):57
60. Corradini P, Vitolo U, Rambaldi A, et al. Intensified chemo-immunotherapy with or without stem cell transplantation in newly diagnosed patients with peripheral t-cell lymphoma. Leukemia 2014;28(9):1885-91
61. Ogura M, Ishida T, Hatake K, et al. Multicenter phase II study of mogamulizumab (kw-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral t-cell lymphoma and cutaneous t-cell lymphoma. J Clin Oncol 2014;32(11):1157-63
62. Ishida T, Inagaki H, Utsunomiya A, et al. Cxc chemokine receptor 3 and cc chemokine receptor 4 expression in T-cell and NK-cell lymphomas with special reference to clinicopathological significance for peripheral t-cell lymphoma, unspecified. Clin Cancer Res 2004;10(16):5494-500
63. Duvic M, Pinter-Brown LC, Foss FM, et al. Phase I/II study of mogamulizumab, a defucosylated anticcr4 antibody, in previously treated patients with cutaneous t-cell lymphoma. Blood 2015;125(12):1883-9
64. Zinzani PL, Coiffier B, Radford J, et al. A phase II open-label, multi-center study of anti-ccr4 monoclonal antibody mogamulizumab (kw-0761) in patients with previously treated peripheral t-cell lymphoma (PTCL). ASH Annual Meeting Abstract 2014;124:abstract 1763
65. Kumar A, Younes A. Role of CD30 targeting in malignant lymphoma. Curr Treat Options Oncol 2014;15(2):210-25
66. Mir SS, Richter BW, Duckett CS. Differential effects of CD30 activation in anaplastic large cell lymphoma and Hodgkin disease cells. Blood 2000;96(13):4307-12
67. Katz J, Janik JE, Younes A. Brentuximab vedotin (sgn-35). Clinical Cancer Res 2011;17(20):6428-36
68. Francisco JA, Cerveny CG, Meyer DL, et al. Cac10-vcmmae, an anti-CD30-monomethyl auristatin e conjugate with potent and selective antitumor activity. Blood 2003;102(4):1458-65
69. Younes A, Bartlett NL, Leonard JP, et al. Brentuximab vedotin (sgn-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010;363(19):1812-21
70. Fanale MA, Forero-Torres A, Rosenblatt JD, et al. A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies. Clin Cancer Res 2012;18(1):248-55
71. Pro B, Advani R, Brice P, et al. Brentuximab vedotin (sgn-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: Results of a phase II study. J Clin Oncol 2012;30(18):2190-6
72. Pro B, Advani R, Brice P, et al. Four-year survival data from an ongoing pivotal phase 2 study of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma. ASH Annual Meeting Abstract 2014;124:abstract 3095
73. Horwitz SM, Advani RH, Bartlett NL, et al. Objective responses in relapsed t-cell lymphomas with single-agent brentuximab vedotin. Blood 2014;123(20):3095-100
74. Fanale MA, Horwitz SM, Forero-Torres A, et al. Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral t-cell lymphomas: Results of a phase I study. J Clin Oncol 2014;32(28):3137-43
75. Sharman JP, Oki Y, Advani RH, et al. A phase 2 study of brentuximab vedotin in patients with relapsed or refractory CD30-positive non-Hodgkin lymphomas: Interim results in patients with DLBCL and other b-cell lymphomas. ASH Annual Meeting Abstract 2013;122:abstract 848
76. Bartlett NL, Smith MR, Advani R, et al. Brentuximab vedotin monotherapy in DLBCL patients with undetectable CD30: Preliminary results from a phase 2 study. ASH Annual Meeting Abstract 2014;124:abstract 629
77. Yasenchak CA, Farber CM, Budde LE, et al. Brentuximab vedotin in combination with RCHOP as front-line therapy in patients with DLBCL: interim results from a phase II study. ASH Annual Meeting Abstract 2014;124:abstract 1745
78. Afable M, Caimi PF, Hosing C, et al. Brentuximab vedotin (BV) does not impair autologous peripheral blood stem cell mobilization and collection in refractory/relapsed CD30+ lymphoma patients undergoing high-dose chemotherapy and autologous stem cell transplant (HDC-ASCT). ASH Annual Meeting Abstract 2014;124:abstract 3854
79. Palanca-Wessels MC, Flinn IW, Sehn LH, et al. A phase I study of the anti-CD79b antibody-drug conjugate (ADC) dcds4501a targeting CD79b in relapsed or refractory b-cell non-Hodgkin's lymphoma (NHL). ASH Annual Meeting Abstracts 2012;120(21):56
80. Chen AI, Lebovic D, Brunvand MW, et al. Final results of a phase I study of the anti-CD22 antibody-drug conjugate (ADC) dcdt2980s with or without rituximab (rtx) in patients (pts) with relapsed or refractory (r/r) b-cell non-Hodgkin's lymphoma (NHL). ASH Annual Meeting Abstract 2013;122:abstract 4399
81. Morschhauser F, Flinn I, Advani RH, et al. Updated results of a phase II randomized study (ROMULUS) of polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed/refractory non-Hodgkin lymphoma. ASH Annual Meeting Abstract 2014;124:abstract 4457
82. Ogura M, Tobinai K, Hatake K, et al. Phase i study of inotuzumab ozogamicin (cmc-544) in Japanese patients with follicular lymphoma pretreated with rituximab-based therapy. Cancer Sci 2010;101(8):1840-5
83. Ogura M, Tobinai K, Hatake K, et al. Phase i study of inotuzumab ozogamicin (cmc-544) in Japanese patients with follicular lymphoma pretreated with rituximab-based therapy. Cancer Sci 2010;101(8):1840-5
84. Fayad L, Offner F, Smith MR, et al. Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: Results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab. J Clin Oncol 2013;31(5):573-83
85. Younes A, Kim S, Romaguera J, et al. Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate sar3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory b-cell lymphoma. J Clin Oncol 2012;30(22):2776-82
86. Ribrag V, Dupuis J, Tilly H, et al. A dose-escalation study of sar3419, an anti-CD19 antibody maytansinoid conjugate, administered by intravenous infusion once weekly in patients with relapsed/refractory b-cell non-Hodgkin lymphoma. Clin Cancer Res 2014;20(1):213-20
87. Moskowitz CH, Forero-Torres A, Shah BD, et al. Interim analysis of a phase 1 study of the antibody-drug conjugate sgn-cd19a in relapsed or refractory b-lineage non-Hodgkin lymphoma. ASH Annual Meeting Abstract 2014;124:abstract 1741
88. Bargou R, Leo E, Zugmaier G, et al. Tumor regression in cancer patients by very low doses of a t cell-engaging antibody. Science 2008;321(5891):974-7
89. Viardot A, Goebeler M, Hess G, et al. Treatment of relapsed/refractory diffuse large b-cell lymphoma with the bispecific t-cell engager (Bite) antibody construct blinatumomab: Primary analysis results from an open-label, phase II study. ASH Annual Meeting Abstract 2014;124:abstract 4460
90. Page DB, Postow MA, Callahan MK, et al. Immune modulation in cancer with antibodies. Annu Rev Med 2014;65:185-202
91. Schneider H, Downey J, Smith A, et al. Reversal of the TCR stop signal by CTLA-4. Science 2006;313(5795):1972-5
92. Prieto PA, Yang JC, Sherry RM, et al. Ctla-4 blockade with ipilimumab: Longterm follow-up of 177 patients with metastatic melanoma. Clin Cancer Res 2012;18(7):2039-47
93. Ansell SM, Hurvitz SA, Koenig PA, et al. Phase i study of ipilimumab, an anti-ctla-4 monoclonal antibody, in patients with relapsed and refractory b-cell non-Hodgkin lymphoma. Clin Cancer Res 2009;15(20):6446-53
94. Bashey A, Medina B, Corringham S, et al. CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation. Blood 2009;113(7):1581-8
95. Davids MS, Kim HT, Costello CL, et al. A multicenter phase I study of ctla-4 blockade with ipilimumab for relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation. ASH Annual Meeting Abstract 2014;124:abstract 3964
96. Keir ME, Liang SC, Guleria I, et al. Tissue expression of pd-l1 mediates peripheral t cell tolerance. J Exp Med 2006;203(4):883-95
97. Dong H, Strome SE, Salomao DR, et al. Tumor-associated b7-h1 promotes t-cell apoptosis: A potential mechanism of immune evasion. Nat Med 2002;8(8):793-800
98. Andorsky DJ, Yamada RE, Said J, et al. Programmed death ligand 1 is expressed by non-Hodgkin lymphomas and inhibits the activity of tumor-associated t cells. Clin Cancer Res 2011;17(13):4232-44
99. Butte MJ, Keir ME, Phamduy TB, et al. Programmed death-1 ligand 1 interacts specifically with the b7-1 costimulatory molecule to inhibit t cell responses. Immunity 2007;27(1):111-22
100. Armand P, Nagler A, Weller EA, et al. Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large b-cell lymphoma: Results of an international phase II trial. J Clin Oncol 2013;31(33):4199-206
101. Westin JR, Chu F, Zhang M, et al. Safety and activity of pd1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: A single group, open-label, phase II trial. Lancet Oncol 2014;15(1):69-77
102. Ansell SM, Lesokhin AM, Borrello I, et al. Pd-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 2015;372(4):311-19
103. Lesokhin AM, Ansell SM, Armand P, et al. Preliminary results of a phase I study of nivolumab (bms-936558) in patients with relapsed or refractory lymphoid malignancies. ASH Annual Meeting Abstract 2014;124:abstract 291
104. Moskowitz CH, Ribrag V, Michot J-M, et al. Pd-1 blockade with the monoclonal antibody pembrolizumab (mk-3475) in patients with classical Hodgkin lymphoma after brentuximab vedotin failure: Preliminary results from a phase 1b study (keynote-013). ASH Annual Meeting Abstract 2014;124:abstract 290
105. Goede V, Fischer K, Busch R, et al. Obinutuzumab plus chlorambucil in patients with cll and coexisting conditions. N Engl J Med 2014;370(12):1101-10
106. Golay J, Semenzato G, Rambaldi A, et al. Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics. mAbs 2013;5(6):826-37
107. O'Brien SM, Kantarjian H, Thomas DA, et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 2001;19(8):2165-70
108. Roit FD, Engelberts PJ, Taylor RP, et al. Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: Implications for combination therapy. Haematologica 2015;100(1):77-86
109. Herter S, Sagiv-Barfi I, Chester C, et al. Obinutuzumab (GA101) is less prone to antagonism of immune effector function by ibrutinib than rituximab in vitro and in vivo. ASH Annual Meeting Abstract 2014;124:abstract 1765